Agios_2021_Logo.png
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
15 juin 2024 08h45 HE | Agios Pharmaceuticals, Inc.
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights...
Agios_2021_Logo.png
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
06 juin 2024 09h00 HE | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios_2021_Logo.png
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
03 juin 2024 06h30 HE | Agios Pharmaceuticals, Inc.
– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key...
Agios_2021_Logo.png
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
30 mai 2024 16h05 HE | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios_2021_Logo.png
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
28 mai 2024 07h00 HE | Agios Pharmaceuticals, Inc.
– Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million Upfront upon FDA Approval of Vorasidenib; Agios to Share in Economics Above Certain...
Agios_2021_Logo.png
Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress
14 mai 2024 10h00 HE | Agios Pharmaceuticals, Inc.
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from...
Agios_2021_Logo.png
Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024
06 mai 2024 07h00 HE | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios_2021_Logo.png
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024
03 mai 2024 07h00 HE | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios_2021_Logo.png
Agios Reports Business Highlights and First Quarter 2024 Financial Results
02 mai 2024 07h00 HE | Agios Pharmaceuticals, Inc.
– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from the...
Agios_2021_Logo.png
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
18 avr. 2024 07h00 HE | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...